Trial reportBMC anesthesiology2026
Efficacy of remimazolam besylate versus propofol on hemodynamics during anesthetic induction in elderly patients undergoing bronchoscopy: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe effect of remimazolam besylate versus propofol on hemodynamics during bronchoscopy remains uncertain.
aimTo test the hypothesis that remimazolam besylate can provide a more stable hemodynamic profile than propofol in the elderly for bronchoscopy under general anesthesia and calculate the optimal induction doses.
methodsA total of 232 patients aged ≥ 65 years who underwent bronchoscopy were enrolled. Participants were randomly divided into the remimazolam besylate group or propofol group for sedation. The patients received titrated induction with remimazolam besylate or propofol combined with remifentanil and maintenance with assigned agents. Vital signs and bispectral index (BIS) changes were monitored. The cognitive test was performed before and after operation. The primary outcome was the incidence of hypotension during induction. Secondary key outcomes included average real variability of mean arterial pressure, titrated dose of remimazolam besylate and propofol during induction, and the BIS changes. Other outcomes included baseline characteristics, intraoperative anesthesia-related data, and other adverse events.
resultsThe remimazolam besylate group had a significantly lower incidence of hypotension during anesthetic induction (28.44% vs. 73.33%,95% CI 1.88-3.56, P < 0.001). The average real variability of mean arterial pressure of remimazolam besylate group was 8.25 ((Interquartile range [IQR] 6.33-11.50) mmHg/min smaller than that 12.33 (IQR 9.00-14.67) mmHg/min in propofol group (P < 0.001). The optimal dose of remimazolam besylate by titration during induction was 0.16 (IQR 0.15-0.18) mg/kg. The mean BIS values in remimazolam besylate group was higher than that in propofol group [59.35 (IQR 53.15-65.11) vs. 55.13 (IQR 51.72-61.75), P < 0.001].
conclusionRemimazolam besylate was superior to propofol in terms of hemodynamics for the elderly undergoing bronchoscopy. Furthermore, we proposed a titrated dose of remimazolam besylate 0.16 mg/kg during induction in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.